Mirae is building a new model for managing autoimmune disease and other complex chronic conditions, starting with inflammatory bowel disease. The company's conversational AI turns everyday patient input into structured, longitudinal insight, enabling earlier intervention and more informed treatment decisions. Developed in collaboration with researchers at the University of Oxford and designed for integration into clinical workflows, Mirae connects patient experience, clinical data, and peer-reviewed evidence into a continuous system of care. By extending the reach of specialty medicine beyond episodic visits, Mirae aims to make high-quality, data-driven care more consistent, more responsive, and more accessible across patient populations
Mirae
- Health
- London, United Kingdom
- £4m
- miraehealth.com
- Update Information
More venture news
- 3 Nov 2026

1nhaler1nhaler lands a £2m follow-on round led by Archangels to test its pop-up cardboard asthma inhaler in patients
Follow-onHealth - 20 Oct 2026

XRlabsXRlabs raises a £6.5m seed round led by Playground Global to embed AI Surgical Intelligence into operating rooms
SeedHealth - 17 Nov 2025

1nhaler1nhaler secures £1.5m in further seed funding led by Archangels to advance its pop-up cardboard inhaler
ExtensionHealth
